当前位置:首页 - 行情中心 - 安科生物(300009) - 财务分析 - 现金流量表

安科生物

(300009)

  

流通市值:98.35亿  总市值:133.49亿
流通股本:12.31亿   总股本:16.71亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,102,593,087.63511,493,367.952,516,919,971.41,942,518,539.31
  收到其他与经营活动有关的现金12,230,380.295,657,088.2434,069,524.520,924,369.73
  经营活动现金流入小计1,114,823,467.92517,150,456.192,550,989,495.91,963,442,909.04
  购买商品、接受劳务支付的现金165,843,884.872,636,077.89200,000,902.21253,992,435.56
  支付给职工以及为职工支付的现金255,120,502.44102,873,486.63499,222,102.66396,052,356.08
  支付的各项税费124,803,599.548,302,502.66236,279,907.58182,425,373.5
  支付其他与经营活动有关的现金296,558,597.61152,507,719.2752,266,112.43575,134,446.28
  经营活动现金流出小计842,326,584.35376,319,786.381,687,769,024.881,407,604,611.42
  经营活动产生的现金流量净额272,496,883.57140,830,669.81863,220,471.02555,838,297.62
二、投资活动产生的现金流量:
  收回投资收到的现金1,131,909,914.09954,700,0001,150,037,035.43998,815,662.41
  取得投资收益收到的现金23,701,443.7511,499,624.9220,764,621.4814,942,163.64
  处置固定资产、无形资产和其他长期资产收回的现金净额145,485.046,00017,593,923.97441,709.56
  处置子公司及其他营业单位收到的现金净额----1,924,052.25
  收到的其他与投资活动有关的现金1,105,395.57467,024.453,299,832.993,187,300.96
  投资活动现金流入小计1,156,862,238.45966,672,649.371,191,695,413.871,015,462,784.32
  购建固定资产、无形资产和其他长期资产支付的现金43,580,360.2624,168,266.25126,891,933.5654,382,690.71
  投资支付的现金923,085,135.151,107,186,0801,516,958,400.481,172,426,545.09
  支付其他与投资活动有关的现金--845,846.49-
  投资活动现金流出小计966,665,495.411,131,354,346.251,644,696,180.531,226,809,235.8
  投资活动产生的现金流量净额190,196,743.04-164,681,696.88-453,000,766.66-211,346,451.48
三、筹资活动产生的现金流量:
  吸收投资收到的现金--23,991,248.283,000,000
  其中:子公司吸收少数股东投资收到的现金---3,000,000
  取得借款收到的现金70,967,920.89-7,000,0007,000,000
  收到其他与筹资活动有关的现金---23,991,248.28
  筹资活动现金流入平衡项目0-00
  筹资活动现金流入小计70,967,920.89-30,991,248.2833,991,248.28
  偿还债务支付的现金--5,000,0005,000,000
  分配股利、利润或偿付利息支付的现金427,086,232.449,204,420416,774,267.93418,080,540.88
  其中:子公司支付给少数股东的股利、利润--3,295,7604,680,460
  支付其他与筹资活动有关的现金63,618,708.9342,474,876.3572,945,601.2363,807,982.79
  筹资活动现金流出小计490,704,941.3751,679,296.35494,719,869.16486,888,523.67
  筹资活动产生的现金流量净额-419,737,020.48-51,679,296.35-463,728,620.88-452,897,275.39
四、汇率变动对现金及现金等价物的影响-548,881.03-166,960.35-6,894,791.48-3,069,341.75
五、现金及现金等价物净增加额42,407,725.1-75,697,283.77-60,403,708-111,474,771
  加:期初现金及现金等价物余额238,201,226.97238,201,226.97298,604,934.97298,604,934.97
  期末现金及现金等价物余额280,608,952.07162,503,943.2238,201,226.97187,130,163.97
补充资料:
  净利润340,305,904.64-747,338,705.69-
  资产减值准备1,267,065.92-28,045,640.38-
  固定资产和投资性房地产折旧46,983,511.93-82,806,998.99-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧46,983,511.93-82,806,998.99-
  无形资产摊销16,018,493.2-32,721,735.7-
  长期待摊费用摊销1,266,004.04-2,874,413.64-
  处置固定资产、无形资产和其他长期资产的损失-149,780.75--6,301,460.04-
  固定资产报废损失147,480.46-383,093.13-
  公允价值变动损失-3,319,536.98--1,881,347.93-
  财务费用-500,502.55-1,421,146.95-
  投资损失-7,238,901.06--18,254,666.16-
  递延所得税3,778,337.29--20,967,934.27-
  其中:递延所得税资产减少3,783,455.63--19,542,147.14-
    递延所得税负债增加-5,118.34--1,425,787.13-
  存货的减少-33,260,664.43-14,143,928.99-
  经营性应收项目的减少-81,007,910.64--129,395,848.59-
  经营性应付项目的增加-19,367,418.07-97,031,592.16-
  其他5,499,166.92-24,843,963.77-
  现金的期末余额280,608,952.07-238,201,226.97-
  减:现金的期初余额238,201,226.97-298,604,934.97-
  现金及现金等价物的净增加额42,407,725.1--60,403,708-
公告日期2026-08-262026-04-242026-03-312025-10-28
审计意见(境内)标准无保留意见
TOP↑